REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)
REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease
Sponsor: Merck Sharp & Dohme LLC
This PHASE3 trial investigates Atherosclerotic Cardiovascular Disease and is currently ongoing. Merck Sharp & Dohme LLC leads this study, which shows 14 recorded versions since 2011 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 9 earlier versions
-
Nov 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Unknown Status → Active Not Recruiting
-
May 2020 — Jul 2020 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Apr 2019 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .